Various Advanced Cancer Clinical Trial
Official title:
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02488759 -
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01986218 -
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02387996 -
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03143153 -
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
|
Phase 3 | |
| Completed |
NCT03130959 -
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT03138486 -
A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab.
|
Phase 2 |